Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 16/20 | 0.71 |
| ▸ | GAA | P10253 | 16/20 | 0.71 |
| ▸ | SI | P14410 | 16/20 | 0.71 |
| ▸ | MGAM2 | Q2M2H8 | 16/20 | 0.71 |
| ▸ | ESR1 | P03372 | 1/20 | 0.67 |
| ▸ | CBFB | Q13951 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2578465 | 0.88 | CBFB (0.73) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL5074029 | 0.87 | MGAM (0.76) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL30615069 | 0.87 | MGAM (0.76) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL3140429 | 0.85 | MGAM (0.59) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL6056826 | 0.85 | MGAM (0.77) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL5201195 | 0.84 | MGAM (0.72) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL15319142 | 0.84 | ESR1 (0.59) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL5201203 | 0.84 | MGAM (1.00) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL353891 | 0.83 | PARP1 (0.56) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL10695650 | 0.82 | MGAM (1.00) | MGAMGAASIMGAM2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140100245-A1 | Antiviral Drugs for Treatment of Arenvirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2014-04-10 | — | — | US | claimed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | claimed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | claimed |
| US-20140100245-A1 | Antiviral Drugs for Treatment of Arenvirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2009123776-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| EP-0513966-B1 | Bis-bibenzimidazole composition | ZENECA LTD (GB) | 1998-04-29 | — | — | EP | disclosed |
| US-5258524-A | Solvent extraction of zinc | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-11-02 | — | — | US | disclosed |
| EP-0513966-A2 | Bis-bibenzimidazole composition | ZENECA LIMITED (GB) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100245-A1 | Antiviral Drugs for Treatment of Arenvirus Infection | HAVCR2, ZC3HAV1, SARS1 | MGAM 2818/4885GAA 46/4885SI 1758/4885 |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | ZC3HAV1, EIF2AK2, SARS1 | MGAM 1181/4885GAA 26/4885SI 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.